TB PRACTECAL: launch event
Read: All MSF updates on COVID-19
Read more
In Nukus, Karakalpakstan, in the west of Uzbekistan, we treat patients for tuberculosis (TB) under the PRACTECAL clinical trial.

The trial combines the first new TB drugs available in over 50 years with existing drugs to treat drug-resistant forms of the disease. Uzbekistan is among the top 27 countries with the highest rates of multidrug-resistant TB (MDR-TB).

We also treat children with TB with a shorter regimen of nine months, instead of the usual 12 months or more, and is conducting research into the results.

In the capital, Tashkent, we support the regional AIDS centre, with the aim of increasing access to diagnosis and care for patients living with HIV and treating co-infections.

We are currently responding to the coronavirus COVID-19 pandemic in the country.

In 2018

To treat or not to treat? Implementation of DOTS in Central Asia

Project Update 9 Jul 2003

Responding to an environmental health disaster in Central Asia

Project Update 9 Jul 2003

Full TB coverage in Khorezm region of Uzbekistan

Project Update 23 Jan 2003

Operational research programme in Aral Sea claims first success

Project Update 5 Jul 2001

Tuberculosis control through DOTS treatment to start in Dashoguz City

Press Release 31 Jul 2000

Charity calls for help for people of Aral Sea area

In the Media 17 Mar 2000